Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Braun, 1998, Prevalence of spondylarthropathies in HLA B27-positive and negative blood donors, Arthritis Rheum, 41, 58, 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G

Khan, 2000, Update: the twenty subtypes of HLA-B27, Curr Opin Rheumatol, 12, 235, 10.1097/00002281-200007000-00001

Sieper, 1995, Pathogenesis of Spondylarthropathies: persistent bacterial antigen, autoimmunity, or both?, Arthritis Rheum, 38, 1547, 10.1002/art.1780381105

Braun, 2000, Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response?, Ann Rheum Dis, 59, 985, 10.1136/ard.59.12.985

Braun, 1998, Radiologic diagnosis and pathology of the spondyloarthropathies, Rheum Dis Clin North Am, 24, 697, 10.1016/S0889-857X(05)70038-7

Zink, 2000, Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centres, J Rheumatol, 27, 613

Boonen, 2001, Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients, Ann Rheum Dis, 60, 353, 10.1136/ard.60.4.353

Leirisalo-Repo, 1998, Prognosis, course of disease, and treatment of the spondyloarthropathies, Rheum Dis Clin North Am, 24, 737, 10.1016/S0889-857X(05)70039-9

Ward, 1999, Quality of life in patients with ankylosis spondylitis: a survey of 175 patients, Arthritis Care Res, 12, 247, 10.1002/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H

Maini, 1999, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, Lancet, 354, 1932, 10.1016/S0140-6736(99)05246-0

Sandborn, 1999, Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety, Inflamm Bowel Dis, 5, 119, 10.1097/00054725-199905000-00008

Van den Bosch, 2000, Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms, Lancet, 356, 1821, 10.1016/S0140-6736(00)03239-6

Antoni, 1999, Successful treatment of severe psoriatic arthritis with infliximab, Arthritis Rheum, 42, S371

Mease, 2000, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 385, 10.1016/S0140-6736(00)02530-7

Van Oosten, 1996, Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2, Neurology, 47, 1531, 10.1212/WNL.47.6.1531

Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202

Braun, 1995, Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis, Arthritis Rheum, 38, 499, 10.1002/art.1780380407

Brandt, 2000, Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab, Arthritis Rheum, 43, 1346, 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E

Van der Linden, 1984, Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria, Arthritis Rheum, 27, 361, 10.1002/art.1780270401

Garrett, 1994, A new approach to defining disease status in ankylosing spondylitis. The Bath ankylosing spondylitis disease activity index, J Rheumatol, 21, 2286

Van der Heijde, 1997, Preliminary core sets for endpoints in ankylosing spondylitis, J Rheumatol, 24, 2225

Calin, 1994, A new approach to defining functional ability in ankylosing spondylitis. The Bath ankylosing spondylitis functional index, J Rheumatol, 21, 2286

Jenkinson, 1994, Defining spinal mobility in ankylosing spondylitis. The Bath ankylosing spondylitis metrology index, J Rheumatol, 21, 1694

Anderson, 2001, ASAS preliminary criteria for short term improvement in ankylosing spondylitis, Arthritis Rheum, 44, 1876, 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F

Ware, 1992, The MOS 36-item short-form health survey (SF 36). Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002

1994

Mackay, 1998, The Bath ankylosing spondylitis radiology index (BASRI), Arthritis Rheum, 41, 2263, 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.0.CO;2-I

Dougados, 2001, Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug, Arthritis Rheum, 44, 180, 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K

Holm, 1979, A simple sequentially rejective multiple test procedure, Scand J Stat, 6, 65

Brandt, 2002, Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor α monoclonal antibody infliximab, J Rheumatol, 44, 2936

Spoorenberg, 1999, Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis, J Rheumatol, 26, 980

Jones, 1996, Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors, J Rheumatol, 23, 487

Brandt, 2002, Treatment of patients with severe ankylosing spondylitis with infliximab—a one year follow up, Arthritis Rheum, 44, 2936, 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-M

Spoorenberg, 1999, Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year, J Rheumatol, 26, 997

Braun, 1994, Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients, Arthritis Rheum, 37, 1039, 10.1002/art.1780370709

Keane, 2001, Tuberculosis Associated with Infliximab, a tumor necrosis factor-neutralizing agent, N Engl J Med, 15, 1098, 10.1056/NEJMoa011110